EGFR Amplification LPS003 - Detail

EGFR (also known as HER1) Epidermal Growth Factor Receptor on chromosome band 7p11.2 is a type I tyrosine kinase receptor for members of the epidermal growth factor family. Binding of the EGFR to epidermal growth factor protein leads to cell proliferation. Abnormally elevated EGFR kinase activity can lead to proliferative diseases such as non-small-cell lung carcinoma (NSCLC), which accounts for 80-85% of all lung cancers¹ and less frequently in breast cancer² amongst others. There are three small molecule EGFR kinase inhibitor drugs in clinical use (gefitinib, erlotinib and lapatinib) and several others are currently undergoing clinical development³. Approximately 10% of lung cancer patients have rapid and dramatic response to these Tyrosine Kinase Inhibitors (TKIs)^4,5. FISH has proven to be useful for determining the status and therefore selection of NSCLC patients for treatment with EGFR TKIs⁶.

Reference:/Bibliographie/Literatur/Bibliografia

1. Jemal A 2006 CA Cancer J Clin; 56:106-130
2. Bhargava R et al. 2005 Modern Path; 18:1027-1033
3. Hegymegi-Barakonyi B 2009 Curr Opin Mol Ther. Jun;11(3):308-21
4. Lynch TJ et al 2004 N E J Med. 350:2129-2139
5. Pao W et al 2004 101:13306-13311
6. Fred R. Hirsch et al 2008 JCO 26 (20): 3351-3357